Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcus Biosciences Inc.

8.52
-0.2400-2.74%
Volume:750.03K
Turnover:6.36M
Market Cap:902.14M
PE:-2.03
High:8.75
Open:8.75
Low:8.36
Close:8.76
Loading ...

Arcus Biosciences Announces New Stock Option and Restricted Stock Unit Grants for Employee Inducement

Reuters
·
Yesterday

Arcus Biosciences Inc. Concluded Annual Stockholders Meeting

Reuters
·
13 Jun

Arcus Biosciences Announces New Employee Stock Options and Restricted Stock Units Under 2020 Inducement Plan

Reuters
·
11 Jun

Wells Fargo Sticks to Its Buy Rating for Arcus Biosciences (RCUS)

TIPRANKS
·
04 Jun

Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Arcus Biosciences (RCUS)

TIPRANKS
·
04 Jun

Arcus Biosciences (RCUS) Gets a Buy from Truist Financial

TIPRANKS
·
02 Jun

Arcus Biosciences presented data for casdatifan plus cabozantinib

TIPRANKS
·
02 Jun

Arcus Biosciences Announces Promising Initial Data for Casdatifan Plus Cabozantinib in Metastatic Kidney Cancer, Prepares to Launch Phase 3 PEAK-1 Study

Reuters
·
01 Jun

Initial Data From the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients With Metastatic Kidney Cancer Had a Confirmed Response

THOMSON REUTERS
·
01 Jun

Arcus Biosciences Inc - ARC-20 Study Shows 46% Response Rate in Metastatic Kidney Cancer

THOMSON REUTERS
·
01 Jun

Arcus Biosciences Grants Employment Inducement Options and Stock Units to New Employees

Reuters
·
28 May

Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

TIPRANKS
·
23 May

Arcus Biosciences Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
09 May

Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating

MT Newswires Live
·
09 May

Truist Financial Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

TIPRANKS
·
09 May

Arcus Biosciences Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
08 May

Arcus Biosciences Is Maintained at Overweight by Wells Fargo

Dow Jones
·
07 May

Stock Track | Arcus Biosciences Plummets 8% as Wells Fargo Slashes Price Target

Stock Track
·
07 May

Arcus Biosciences Inc : Wells Fargo Cuts Target Price to $26 From $29

THOMSON REUTERS
·
07 May

Arcus Biosciences (RCUS) Gets a Buy from Barclays

TIPRANKS
·
07 May